Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms SR-0813 |
Target |
Action degraders |
Mechanism MLLT1 degraders(MLLT1 super elongation complex subunit degraders), MLLT3 degraders(MLLT3 super elongation complex subunit degraders) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC25H32N6O3S |
InChIKeyGPMTWAPXRJMXCC-UHFFFAOYSA-N |
CAS Registry2597186-19-9 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| acute leukemia | Preclinical | United States | 26 May 2021 |





